|
[1]LIU J,LIANG W,JING W,et al.Countdown to 2030:Eliminating hepatitis B disease,China[J].Bull World Health Organ,2019,97(3):230-238．
|
|
[2]GIOULEME OI,VYZANTIADIS TA,NIKOLAIDIS NL,et al.Pathogenesis of osteoporosis in liver cirrhosis[J].Hepatogastroenterology,2006,53(72):938-943．
|
|
[3]NAKCHBANDI IA.Osteoporosis and fractures in liver disease:Relevance,pathogenesis and therapeutic implications[J].World J Gastroenterol,2014,20(28):9427-9438．
|
|
[4]CAO Y,XU XY.Association between osteopenia and osteoporosis in patients with viral hepatitis[J].Natl Med J China,2014,94(43):3450-3452.(in Chinese)曹颖，徐小元．病毒性肝炎患者的骨量减少与骨质疏松关系[J]．中华医学杂志，2014,94(43):3450-3452．
|
|
[5]CHEN CH,LIN CL,KAO CH.Association between chronic hepatitis B virus infection and risk of osteoporosis:A nationwide populationbased study[J].Medicine(Baltimore),2015,94(50):e2276．
|
|
[6]YENICE N,GMRAH M,MEHTAP O,et al.Assessment of bone metabolism and mineral density in chronic viral hepatitis[J].Turk JGastroenterol,2006,17(4):260-266．
|
|
[7]ZHANG Q,CHENG J,ZHAO CS,et al.Study on the changes of serum osteoprotegerin and receptor activator for nuclear factor-κB ligand in patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis(Electronic Edition),2013,7(6):850-854.(in Chinese)张强，成军，赵昌松，等．慢性乙型肝炎患者血清骨保护素和核因子κB受体活化因子配体变化的研究[J/CD]．中华实验和临床感染病杂志(电子版)，2013,7(6):850-854．
|
|
[8]SCHIEFKE I,FACH A,WIEDMANN M,et al.Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection[J].World J Gastroenterol,2005,11(12):1843-1847．
|
|
[9]SUN YL,ZHANG LH,FANG HL,et al.Measurement of the activities of interleukin-1,interleukin-6,and tumor necrosis factor-αin patients with viral hepatitis[J].Chin J Microbiol Immunol,1994,14(3):187-189.(in Chinese)孙永良，张立煌，方海林，等．病毒性肝炎患者IL-1、IL-6和TNFα活性的检测[J]．中华微生物学和免疫学杂志，1994,14(3):187-189．
|
|
[10]LEE YM,FUJIKADO N,MANAKA H,et al.IL-1 plays an important role in the bone metabolism under physiological conditions[J].Int Immunol,2010,22(10):805-816．
|
|
[11]WU Q,ZHOU X,HUANG D,et al.IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro[J].Cell Physiol Biochem,2017,41(4):1360-1369．
|
|
[12]NAKCHBANDI IA,MITNICK MA,LANG R,et al.Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism[J].J Clin Endocrinol Metab,2002,87(11):4946-4951．
|
|
[13]BLASCHKE M,KOEPP R,CORTIS J,et al.IL-6,IL-1β，and TNFαonly in combination influence the osteoporotic phenotype in Crohn's patients via bone formation and bone resorption[J].Adv Clin Exp Med,2018,27(1):45-56．
|
|
[14]RUIZ-GASPS,MARTINEZ-FERRER A,GUAABENS N,et al.Effects of bilirubin and sera from jaundiced patients on osteoblasts:Contribution to the development of osteoporosis in liver diseases[J].Hepatology,2011,54(6):2104-2113．
|
|
[15]CHEN RS,YAN DW,WANG JP,et al.Changes in biochemical markers of bone turnover,sex hormones and calcium regulating hormones in male patients with chronic hepatitis B induced liver cirrhosis[J].Chin J Osteoporos,2002,8(3):44-45.(in Chinese)陈如山，阎德文，王建平，等．慢性乙型肝炎性肝硬化症男性患者血清性激素、钙调节激素和骨转换指标的变化[J]．中国骨质疏松杂志，2002,8(3):44-45．
|
|
[16]ROUILLARD S,LANE NE.Hepatic osteodystrophy[J].Hepatology,2001,33(1):301-307．
|
|
[17]TSAI CF,LIU CJ,CHEN TJ,et al.Increased incidence of orthopedic fractures in cirrhotic patients:A nationwide population-based study[J].J Hepatol,2013,58(4):706-714．
|
|
[18]Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol,2017,33(10):1847-1863.(in Chinese)中华医学会肝病学分会．肝硬化腹水及相关并发症的诊疗指南[J]．临床肝胆病杂志，2017,33(10):1847-1863．
|
|
[19]VERBALIS JG,BARSONY J,SUGIMURA Y,et al.Hyponatremiainduced osteoporosis[J].J Bone Miner Res,2010,25(3):554-563．
|
|
[20]LIM LS,FINK HA,BLACKWELL T,et al.Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women[J].J Am Geriatr Soc,2009,57(5):855-862．
|
|
[21]HAMIDI MS,GAJIC-VELJANOSKI O,CHEUNG AM.Vitamin K and bone health[J].J Clin Densitom,2013,16(4):409-413．
|
|
[22]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Endoscopy,Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastricvariceal bleeding incirrhotic portal hypertension[J].J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219．
|
|
[23]ANTOCI V Jr,ADAMS CS,HICKOK NJ,et al.Antibiotics for local delivery systems cause skeletal cell toxicity in vitro[J].Clin Orthop Relat Res,2007,462:200-206．
|
|
[24]HOLTOM PD,PAVKOVIC SA,BRAVOS PD,et al.Inhibitory effects of the quinolone antibiotics trovafloxacin,ciprofloxacin,and levofloxacin on osteoblastic cells in vitro[J].J Orthop Res,2000,18(5):721-727．
|
|
[25]COSTA-RODRIGUES J,MARTINS EG,FERNANDES MH.Induced osteoclastogenesis by fluoroquinolones in unstimulated and stimulated human osteoclast precursor cells[J].Bone,2012,51(1):17-27．
|
|
[26]Liver Failure and Artifical Liver Group,Chinese Society of Infectious Diseases,Chinses Medical Association,Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for diagnosis and treatment of liver failure[J].J Clin Hepatol,2019,35(1):38-44.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝衰竭诊治指南(2018年版)[J]．临床肝胆病杂志，2019,35(1):38-44．
|
|
[27]BROWN TT,HOY J,BORDERI M,et al.Recommendations for evaluation and management of bone disease in HIV[J].Clin Infect Dis,2015,60(8):1242-1251．
|
|
[28] Chinese Society of Osteoporosis and Bone Mineral Research.Gidelines for the diagnosis and management of primary osteoporosis(2017)[J].Chin J Osteoporos,2019,25(3):281-309.(in Chinese)中华医学会骨质疏松和骨矿盐疾病分会．原发性骨质疏松症诊疗指南(2017)[J]．中国骨质疏松杂志，2019,25(3):281-309．
|
|
[29]CAMACHO PM,PETAK SM,BINKLEY N,et al.American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016[J].Endocr Pract,2016,22(Suppl4):1-42．
|
|
[30]ZHANG W,GONG H,SU Z,et al.Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness:An observational study[J].Medicine(Baltimore),2019,98(31):e16628．
|
|
[31]MARQUES A,LOURENO，DA SILVA JA,et al.The burden of osteoporotic hip fractures in Portugal:Costs,health related quality of life and mortality[J].Osteoporos Int,2015,26(11):2623-2630．
|
|
[32]Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J].JClin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089．
|
|
[33]BMEUR C,BUTTERWORTH RF.Nutrition in the management of cirrhosis and its neurological complications[J].J Clin Exp Hepatol,2014,4(2):141-150．
|
|
[34]HAJIABBASI A,SHAFAGHI A,FAYAZI HS,et al.The factors affecting bone density in cirrhosis[J].Hepat Mon,2015,15(4):e26871．
|
|
[35]SHIOMI S,MASAKI K,HABU D,et al.Calcitriol for bone disease in patients with cirrhosis of the liver[J].J Gastroenterol Hepatol,1999,14(6):547-552．
|
|
[36]CASTELO-BRANCO C,CORTS X,FERRER M,et al.Treatment persistence and compliance with a combination of calcium and vitamin D[J].Climacteric,2010,13(6):578-584．
|
|
[37]Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J].J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.
|
DownLoad: